Cervical cancer
Topic: Human Capital: Education, Health and Demographic Dividend · NCERT: Beyond NCERT
Meaning
Cervical cancer is cancer of the cervix, the lower part of the uterus (womb). Persistent (long-lasting) infection with high-risk types of HPV (human papillomavirus) causes the vast majority of cases. It can be prevented in three ways: a vaccine in girlhood, screening (a test that catches early disease) in adult life, and treatment of early disease.
Why it matters in economics: the disease falls only on women and often hits them in their working years. Vaccination is the "preventive medicine" form of health spending, which is a source of human capital. It protects women's health, their earnings and the savings of their households.
Explanation
How the disease develops and where it can be stopped
- Cause
- A girl or woman gets infected with a high-risk type of HPV.
-
If the infection does not clear and stays for years, cells in the cervix can slowly turn into cancer.
-
Three points where the chain can be broken. These match WHO's 90-70-90 targets for 2030. The World Health Assembly adopted them in 2020.
- Vaccinate (the first "90"): 90% of girls fully vaccinated by age 15. This stops the infection before it starts.
- Screen (the "70"): 70% of women screened with a high-performance test (one as good as an HPV test) by 35 and again by 45.
-
Treat (the second "90"): 90% of women found with cervical disease get treatment.
-
Why the age of 14
- The vaccine works best if it is given before likely exposure to HPV. That is why India vaccinates girls at 14.
The vaccine and the single-dose shift
- HPV vaccines were first licensed for two or three doses.
- In April 2022, WHO's SAGE (Strategic Advisory Group of Experts on immunisation) found that one dose protects about as well as two.
- WHO's December 2022 advice allows one or two doses for ages 9-14, and also for girls and young women aged 15-20. WHO calls the single dose an off-label option, meaning it differs from the dosing on the manufacturer's licence.
- By 10 Sep 2024, 57 countries were using one dose. In Oct 2024, Cecolin became the 4th WHO-prequalified (WHO-approved) HPV vaccine cleared for single-dose use.
- Why one dose matters economically
- Each girl needs fewer visits, so cost and logistics fall.
-
The same budget can reach more girls in less time.
-
The open question: vaccines have been used at scale for only about two decades, so nobody yet has 30 years of follow-up on one dose. Vaccinated girls need long-term tracking.
Why vaccination alone cannot meet the 2030 target
- There is a time lag
- The girls vaccinated today are 14. Cervical cancer mostly appears in adult women.
-
So the vaccine prevents almost none of the cancers expected by 2030. Today's adult women are protected only by screening and treatment.
-
Worked example: coverage and gaps
- Annual cohort (all girls born in the same year) ≈ 1.2 crore girls aged 14, based on RGI 2021 estimates.
- Coverage ≈ 87% → about 13% unvaccinated → 0.13 × 1.2 crore ≈ 15 lakh girls still unvaccinated.
- Screening: 10.18 crore screened ÷ 25.42 crore eligible women aged 30+ ≈ 40% (as of 20 July 2025). That is well below the "70" target, and it counts screenings of every type.
Cervical cancer as a human capital issue
- Preventive medicine. Class 11 lists vaccination as the preventive form of health spending, one of the sources of human capital. A one-time vaccine at 14 is a classic preventive investment.
- Fewer lost working years
- A sick worker stays away from work, so output is lost.
-
Cervical cancer strikes adult women. It cuts their labour supply and their care of children.
-
Household poverty
- Cancer treatment can be catastrophic for a family's budget.
- Out-of-pocket spending (money families pay themselves at the point of care) is about 39% of total health spending (National Health Accounts 2021-22).
-
So every case prevented also protects a family's savings.
-
Market failure
- Families may not know the risk, or may doubt the vaccine. This information gap means they demand less vaccination than is good for them.
- That is the case for a free, state-run programme.
In India
- Programme: the National HPV Vaccination Campaign, run by MoHFW. The PM launched it on 28 Feb 2026 from Ajmer, Rajasthan.
- Design
- Free, voluntary and single-dose, for 14-year-old girls, with parental consent.
-
Given at Government health facilities under trained Medical Officers.
-
Safety: the AEFI (Adverse Events Following Immunization) framework, with vaccination sites linked to 24×7 healthcare centres.
- Digital backbone: U-WIN, the digital vaccination registry, handles real-time monitoring, beneficiary tracking, slot booking and downloadable certificates.
- Latest figures (Nov 2026)
- More than 1 crore doses given in under nine months.
- About 87% coverage of an annual cohort of about 1.2 crore girls (RGI 2021).
-
Six States are at 100%: Gujarat, UP, AP, Mizoram, MP and Bihar.
-
Indigenous vaccine: CERVAVAC is India's first indigenously developed cervical cancer vaccine.
- UIP status: as of Dec 2024, the HPV vaccine was not part of the Universal Immunization Programme (UIP).
- Screening
- Runs through the National NCD Portal under NP-NCD (rolled out 2018), for people aged 30 and above.
- Delivered at Ayushman Arogya Mandirs (primary care centres).
- India's main screening test is VIA (visual inspection with acetic acid: a health worker applies a mild acid to the cervix and looks for colour changes).
-
MoHFW reports that an indigenous point-of-care HPV DNA test (done on the spot, without a central lab) has been validated.
-
The screening gap: WHO's India profile (2021) says fewer than 1 in 10 women had been screened in the previous five years.
Don't confuse with
- HPV infection vs cervical cancer: most HPV infections clear on their own. Only persistent high-risk HPV infection leads to cervical cancer.
- Vaccination (primary prevention) vs screening (secondary prevention): the vaccine stops infection in girls before exposure. Screening finds early disease in adult women aged 30 and above. Only screening and treatment can lower cases before 2030.
- Doses vs coverage: "1 crore" counts doses given. "About 87%" is the share of the annual cohort covered. Coverage is measured against an RGI estimate, not a headcount.
- WHO 90-70-90 vs Indonesia 90-75-90: 90-70-90 is WHO's global target for 2030. 90-75-90 is Indonesia's own national version.
Prelims Hooks
- Persistent infection with high-risk HPV types causes the vast majority of cervical cancer cases.
- India's campaign: single dose, 14-year-old girls, free and voluntary, parental consent, launched 28 Feb 2026 from Ajmer, run by MoHFW. U-WIN is the digital platform.
- WHO's 90-70-90 targets for 2030, adopted by the WHA in 2020: 90% of girls vaccinated by age 15, 70% of women screened by 35 and 45, 90% treated.
- SAGE (April 2022): one dose gives protection comparable to two. Trap: "India's campaign uses a 2-dose schedule for girls aged 9-14": FALSE.
- CERVAVAC is India's first indigenous cervical cancer vaccine. As of Dec 2024, the HPV vaccine was outside the UIP.
- Screening runs through NP-NCD / National NCD Portal (2018) for people aged 30 and above. Trap: VIA, India's main test, does not count as WHO's "high-performance test".
Mains Points
- Prevention as human capital investment
- A low-cost single dose at 14 → fewer cancers in women of working age → less lost labour and less catastrophic out-of-pocket spending (about 39% of health spending, NHA 2021-22).
-
Vaccination has external benefits: it also reduces the spread of HPV to others. Markets undersupply goods with external benefits, so free state provision is justified.
-
The vaccine helps only in the long run; screening is the 2030 gap
- Today's adult women depend on screening, which reaches only about 40% of eligible women on the NCD Portal count (July 2025), and fewer than 1 in 10 on WHO's five-year measure.
-
Possible steps:
- move from VIA to indigenous HPV DNA tests;
- add HPV to the UIP so funding is permanent;
- run a catch-up drive for girls aged 15-20, which WHO's 2022 advice allows;
- link U-WIN records to the NCD Portal, so vaccinated girls are called for screening at 30.
-
Equity and federal delivery
- The Union, States and districts deliver the campaign together, and earlier programmes in Bihar, Tamil Nadu and Sikkim were merged into it.
- Coverage still varies by State, so lagging States need targeted catch-up.
- Consent and misinformation are real barriers. ASHAs, ANMs and teachers are used to build parents' trust.